Este sitio requiere JavaScript para funcionar apropiadamente. Por favor modifique sus preferencias o utilice un navegador diferente para continuar.


Usted está a punto de salir de la página web de GSK

Este enlace lo llevará a un sitio web que no pertenece a GSK. GSK no recomienda, aprueba ni acepta responsabilidad por los sitios controlados por terceros.



Three effective molecules in a single daily inhalation – help lessen the impact of COPD in appropriate patients. 1, 2

By combining ICS/LAMA/LABA, TRELEGY Ellipta OD offers proven efficacy vs. BUD/FOR Turbuhaler BD, and a simple medication routine. 1, 2

See Efficacy data

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA. 1

Register today

Receive the latest information about TRELEGY Ellipta.

BD, twice-daily; BUD, budesonide; COPD, chronic obstructive pulmonary disease; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroids; LABA, long-acting β-agonist; LAMA, long acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol


  1. TRELEGY Ellipta Summary of Product Characteristics, 2017. 
  2. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.

TRELEGY Ellipta was developed in collaboration with INNOVIVA Inc.

© 2017 GlaxoSmithKline Group of Companies. TRELEGY and Ellipta are trademarks of the GSK group of companies.

Materials supplied by the above-country business unit to LOCs, for localisation must be subject to local Medical and/or Regulatory review and approval prior to external distribution